Clinical trial NCT00039377 (phase 2, status: completed)
Conditions: adult acute lymphoblastic leukemia in remission
ICD codes: C83.57, C83.50, C91.01, C91.02, C83.52, C83.56, C83.53
Drugs: imatinib mesylate, methotrexate, vincristine sulfate, leucovorin calcium, tacrolimus, etoposide, cyclophosphamide, cytarabine
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Unequivocal histologic diagnosis of ALL

          -  Detection of the t(9;22)(q34;q11) or 3-way variant by metaphase cytogenetics or
             BCR-ABL positive by molecular analysis (RT-PCR or fluorescence in situ hybridization
             [FISH})

          -  Prior Therapy:

               -  Complete or partial remission following one course of induction chemotherapy with
                  an intensive 4 or 5 drug regimen (with or without imatinib mesylate) on a CALGB
                  or SWOG ALL protocol for previously untreated ALL patients

                    -  Note: The double induction regimen of SWOG S0333 is considered to be one
                       course of induction chemotherapy for the purpose of this eligibility
                       criterion; therefore, patients from S0333 may be eligible for this study
                       only after completing the entire double induction regimen

               -  Complete or partial remission following one course of therapy on any standard
                  induction regimen (with or without imatinib mesylate) without prior enrollment on
                  a cooperative group frontline protocol; in these instances, documentation of
                  Philadelphia chromosome (Ph)+ positivity may occur outside a CALGB or SWOG
                  laboratory

                    -  Note: CALGB institutions must enroll patients on CALGB 9862 and submission
                       of an initial sample for the companion trial must occur at time of
                       enrollment on CALGB C10001; enrollment on companion studies CALGB 8461 and
                       9665 is not required

          -  No more than six weeks of prior imatinib mesylate during induction therapy before
             study enrollment

          -  Non-pregnant and non-nursing; treatment under this protocol would expose an unborn
             child to significant risks; women and men of reproductive potential should agree to
             use an effective means of birth control and contraception should continue for three
             months after the last dose of imatinib mesylate (Gleevec) to allow complete clearance
             of drug and its principle metabolites from the body; in women of childbearing
             potential, a pregnancy test will be required at study entry